Novartis was expecting a lot from its PARAGON-HF trial of Entresto in heart failure with preserved ejection fraction (HFpEF) and isn’t letting a missed endpoint scupper the programme.

The Federal Circuit has issued a precedential decision reversing a lower court’s decision that certain claims of Novartis’s ...

Faced with the slow-takeup, in 2016, Novartis started the FortiHFy programme, a series of clinical trials aimed at thoroughly testing Entresto across a range of HF settings which were thought to ...

A U.S. appeals court has lifted a temporary halt it imposed on the launch of a generic version of Novartis's (NYSE:NVS) top-selling cardiac drug Entresto. The U.S. Court of Appeals for the ...

An attorney for MSN declined to comment. India-based MSN's version of Entresto was approved by the U.S. Food and Drug Administration last year. Novartis sued MSN and others seeking to launch ...

In a Jan. 10 precedential ruling by the United States Court of Appeals for the Federal Circuit, the validity of the U.S. patent covering ...